Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04493229
Other study ID # IRB00066646
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date January 2024
Est. completion date January 2026

Study information

Verified date June 2020
Source Wake Forest University Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will examine the effect that a dose of intramuscular (IM) oxytocin (naturally occurring hormone) has on fear of pain and movement and trust in the physical therapist during outpatient rehabilitation after total knee replacement has been performed. Investigators will ask participants to answer questions about fear of pain and movement before several outpatient physical therapy session and investigators will ask participants questions about trust of the physical therapist several times after the outpatient physical therapy sessions.


Description:

The purpose of this study is to determine feasibility of this study design and identify barriers that altered design could bring to overcome these barriers in the design of a large, pragmatic, multi-center clinical trial. It is also designed to estimate the effect size and variance of the main outcome measures, trust and fear, in patients undergoing rehabilitation after total knee arthroplasty (TKA). The study team hypothesizes that intramuscular (IM) oxytocin, in a dose and time determined by a series of previous studies under this grant to target the brain, will enhance trust and reduce fear and that these will be associated with improved outcomes. Again, the study is not designed to test this hypothesis, but to gather the critical data necessary to test it in a large, multi-center clinical trial that would follow this grant. Participants that have decided to undergo unilateral TKA, will come to the Pain Clinical Research Unit at least 48 hours prior to surgery to confirm consent and complete a series of questionnaires. Participants surgery, anesthesia, and postoperative medication and therapy treatment will be routine. On the first outpatient study visit participants will complete a questionnaire of fear about pain and receive an intramuscular injection of oxytocin or placebo in a randomized, double blind manner. At the end of this session participants will complete a questionnaire assessing the degree of trust in the therapist. Physical therapy be will routine, and the fear and trust questionnaires will be completed at the 2nd, 4th, 8th, and last physical therapy session as well as routine measures of progress and function. The primary outcome measure is assessment of effect size and variability of the trust and fear questionnaires on the 1st and 2nd visit.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 2026
Est. primary completion date January 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Male or female > 18 and < 75 years of age, Body Mass Index (BMI) <40. 2. Generally in good health as determined by the Principal Investigator based on prior medical history, American Society of Anesthesiologists physical status 1, 2, or 3. Scheduled for unilateral TKA and postoperative physical therapy at Davie Medical Center. 3. Normal blood pressure (systolic 90-140 mmHg; diastolic 50-90 mmHg) resting heart rate 45-100 beats per minute) without medication or for those with hypertension, pressure controlled with anti-hypertensives and with a resting heart rate 45-100 beats per minute. 4. Female subjects of child-bearing potential and those < 1 year post-menopausal, must be practicing highly effective methods of birth control such as hormonal methods (e.g., combined oral, implantable, injectable, or transdermal contraceptives), double barrier methods (e.g., condoms, sponge, diaphragm, or vaginal ring plus spermicidal jellies or cream), or total abstinence from heterosexual intercourse for a minimum of 1 full cycle before study drug administration. Exclusion Criteria: 1. Hypersensitivity, allergy, or significant reaction to any ingredient of PitocinĀ® 2. Any disease, diagnosis, or condition (medical or surgical) that, in the opinion of the Principal Investigator, would place the subject at increased risk (active gynecologic disease in which increased tone would be detrimental e.g., uterine fibroids with ongoing bleeding), compromise the subject's compliance with study procedures, or compromise the quality of the data 3. Women who are pregnant (positive result for urine pregnancy test at screening visit), women who are currently nursing or lactating, women that have been pregnant within 2 years 4. Subjects with neuropathy, chronic pain, diabetes mellitus, or taking benzodiazepines or pain medications on a daily basis.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Oxytocin
IM Oxytocin
Placebo
Placebo IM

Locations

Country Name City State
United States Wake Forest Baptist Health Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Wake Forest University Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tampa Scale of Kinesiophobia-11 (TSK-11) TSK-11 scale ranges from 11 to 44 with a higher score denoting a worse outcome.
The TSK-11 will be completed prior to the outpatient post-operative physical therapy session
Postoperative Outpatient Physical Therapy Visit 1/study medication administration visit/Baseline
Primary Tampa Scale of Kinesiophobia-11 (TSK-11) TSK-11 scale ranges from 11 to 44 with a higher score denoting a worse outcome.
The TSK-11 will be completed prior to the outpatient post-operative physical therapy session
Postoperative Outpatient Physical Therapy Visit 2, 1-5 days after study medication
Primary Tampa Scale of Kinesiophobia-11 (TSK-11) TSK-11 scale ranges from 11 to 44 with a higher score denoting a worse outcome.
The TSK-11 will be completed prior to the outpatient post-operative physical therapy session
Postoperative Outpatient Physical Therapy Visit 4, 5-10 days after study medication
Primary Tampa Scale of Kinesiophobia-11 (TSK-11) TSK-11 scale ranges from 11 to 44 with a higher score denoting a worse outcome.
The TSK-11 will be completed prior to the outpatient post-operative physical therapy session
Postoperative Outpatient Physical Therapy Visit 8, 7 -20 days after study medication
Primary Tampa Scale of Kinesiophobia-11 (TSK-11) TSK-11 scale ranges from 11 to 44 with a higher score denoting a worse outcome.
The TSK-11 will be completed prior to the outpatient post-operative physical therapy session
Postoperative Outpatient Physical Therapy Final Visit, 10-60 days after study medication
Primary Working Alliance Inventory (WAI) The WAI score ranges from 24 to 72 with a higher score denoting a better outcome.
The WAI will be completed after the outpatient post-operative physical therapy session.
Postoperative Outpatient Physical Therapy Visit 1/study medication administration visit/Baseline
Primary Working Alliance Inventory (WAI) The WAI score ranges from 24 to 72 with a higher score denoting a better outcome.
The WAI will be completed after the outpatient post-operative physical therapy session.
Postoperative Outpatient Physical Therapy Visit 2, 1-5 days after study medication
Primary Working Alliance Inventory (WAI) The WAI score ranges from 24 to 72 with a higher score denoting a better outcome.
The WAI will be completed after the outpatient post-operative physical therapy session.
Postoperative Outpatient Physical Therapy Visit 4, 5-10 days after study medication
Primary Working Alliance Inventory (WAI) The WAI score ranges from 24 to 72 with a higher score denoting a better outcome.
The WAI will be completed after the outpatient post-operative physical therapy session.
Postoperative Outpatient Physical Therapy Visit 8, 7 -20 days after study medication
Primary Working Alliance Inventory (WAI) The WAI score ranges from 24 to 72 with a higher score denoting a better outcome.
The WAI will be completed after the outpatient post-operative physical therapy session.
Postoperative Outpatient Physical Therapy Final Visit, 10-60 days after study medication
Secondary Pain during straight leg raise During the postoperative physical therapy sessions, pain using a 0-10 verbal scale, with 0 equivalent to NO PAIN and 10 equivalent to THE WORST PAIN IMAGINABLE will be measured and the data collected from the electronic medical record. Post-operative outpatient physical therapy sessions, up to 12 weeks post surgery
Secondary Pain after straight leg raise During the postoperative physical therapy sessions, pain using a 0-10 verbal scale, with 0 equivalent to NO PAIN and 10 equivalent to THE WORST PAIN IMAGINABLE will be measured and the data collected from the electronic medical record. Post-operative outpatient physical therapy sessions, up to 12 weeks post surgery
Secondary Physical therapist deems stepping exercise begins; may walk up and down steps During routine physical therapy after this surgery, the therapist determines when the patient is ready to begin stepping exercised during therapy. It is a subjective determination by the therapist. The outcome measure is the number of days since surgery when the therapist notes in the electronic medical record (EMR) that the patient began stepping exercises. Post-operative 24-48 hours after surgery
Secondary Gait speed Gait speed will be measured by the physical therapist at the first physical therapy session and the last physical therapy session and at varying times during physical therapy after surgery using meters/seconds. Distance in meters is divided by the number of seconds.
This data will be recorded in the electronic medical recorded and recorded from the electronic medical record.
Post-operative outpatient physical therapy sessions, up to 12 weeks post surgery
Secondary Average pain score Patients will be asked to verbally state the average pain they have experienced in the 24 hours prior to the scheduled physical therapy session. Average pain will be measured using a verbal pain scale; 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Post-operative outpatient physical therapy sessions, up to 12 weeks post surgery
Secondary Analgesic Consumption Analgesic medications will be recorded from the day previous to each therapy session. Analgesic consumption will be converted into morphine equivalents using a standard conversion table. Post-operative outpatient physical therapy sessions, up to 12 weeks post surgery
See also
  Status Clinical Trial Phase
Recruiting NCT03895489 - Effectiveness of the Journey Total Knee Arthroplasty Versus Two Standard of Care Total Knee Arthroplasty Prostheses N/A
Completed NCT03660943 - A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain Phase 3
Completed NCT04531969 - Comparison of Outpatient and Inpatient Spa Therapy N/A
Completed NCT02848027 - Correlating the Osteoarthritic Knee Microenvironment to Clinical Outcome After Treatment With Regenexx®SD Treatment Phase 3
Completed NCT05160246 - The Instant Effect of Kinesiology Taping in Patients With Knee OA N/A
Recruiting NCT06080763 - Biomechanics and Clinical Outcomes in Responders and Non-Responders
Completed NCT03643588 - The Comparison of HYAJOINT Plus and Hyalgan Hyaluronan Supplement for Knee Osteoarthritis Pain N/A
Active, not recruiting NCT05100225 - Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis Phase 2
Active, not recruiting NCT04061733 - New Hydroxyethyl Cellulose Hydrogel for the Treatment of the Pain of Knee Arthrosis N/A
Completed NCT04051489 - A Novel Smartphone Application for "Smart" Knee Osteoarthritis Trials
Recruiting NCT05546541 - Epidemiology and Nutrition
Recruiting NCT05447767 - Prediction AlgoriThm for regeneraTive Medicine Approach in knEe OA: New Decision-making Process Based on Patient pRofiliNg Phase 2
Not yet recruiting NCT04448106 - Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis Phase 2
Not yet recruiting NCT03225911 - Effect of a Lateral Wedge Insole and Simple Knee Sleeve in Individuals With Knee Osteoarthritis N/A
Completed NCT05070871 - A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women N/A
Completed NCT05703087 - Positive Cueing in Knee Arthroplasty. N/A
Not yet recruiting NCT06042426 - Effects of Perioperative Intravenous Dexamethasone in Clinical Outcomes After Total Knee Arthroplasty in a Hispanic Population Phase 4
Completed NCT03037489 - A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients Phase 2
Terminated NCT02909257 - Motor-Sparing Femoral Nerve Block Dose Phase 4
Not yet recruiting NCT02865174 - Topical Tranexamic Acid and Floseal® in Total Knee Arthroplasty Phase 4